Septerna (SEPN) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Xencor (XNCR) has outperformed Septerna (SEPN) over the past year, gaining 88.6% versus a gain of 65.8%. Xencor is the larger company by market cap ($1.83 billion vs $1.79 billion), about 1.0 times the size, while Septerna is growing revenue faster (+4174.5% vs +13.7%). Xencor converts more of its revenue into profit, with a net margin of -73.2% versus -106.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SEPN | XNCR |
|---|---|---|
| Share price | $38.37 | $24.63 |
| Market cap | $1.79B | $1.83B |
| 1-day change | +3.98% | +0.53% |
| YTD return | +37.63% | +60.88% |
| 1-year return | +65.82% | +88.59% |
| 5-year return | — | -35.98% |
| EPS (TTM) | $-0.54 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $45.95M | $125.58M |
| Revenue growth (YoY) | +4174.51% | +13.65% |
| Net income (latest FY) | $-48.88M | $-91.92M |
| Operating margin | -148.63% | -141.35% |
| Net margin | -106.37% | -73.20% |
| 52-week high | $51.10 | $30.61 |
| 52-week low | $17.55 | $10.38 |
| Distance from 52-week high | -24.91% | -19.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +41.31% | +27.57% |
| Average volume | 390.66K | 1.32M |
| Shares outstanding | 46.68M | 74.35M |
| Employees | 123 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed SEPN by 22.8 percentage points over the past year.
- Xencor is more profitable, keeping -73.2 cents of every revenue dollar as net income versus -106.4 cents for Septerna.
- Septerna grew revenue faster in its latest fiscal year (+4174.51% vs +13.65%).
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
SEPN vs XNCR FAQ
Which is bigger, Septerna or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $1.83B compared with $1.79B for Septerna (SEPN).
Which stock has performed better over the past year, SEPN or XNCR?
XNCR returned +88.59% over the past 12 months, compared with +65.82% for SEPN (price return, excluding dividends). Past performance does not predict future results.
Are Septerna and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.